CKD Bio Corp. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,657
1,105
6,653
9,435
8,016
7,956
Depreciation, Depletion & Amortization
11,713
11,416
10,904
8,997
9,068
8,956
Other Funds
143
973
3,843
1,255
869
2,700
Funds from Operations
13,513
11,284
21,400
19,686
16,215
19,612
Changes in Working Capital
2,589
61
7,061
4,186
4,231
4,076
Net Operating Cash Flow
10,924
11,223
14,339
15,500
20,446
15,536
Capital Expenditures
4,112
2,871
11,919
10,756
9,672
Sale of Fixed Assets & Businesses
32
48
41
82
-
Purchase/Sale of Investments
552
552
72
432
2,975
Net Investing Cash Flow
4,630
3,376
11,950
11,107
12,647
Cash Dividends Paid - Total
1,795
513
513
1,795
2,052
Issuance/Reduction of Debt, Net
11,305
7,347
1,817
1,936
4,802
Net Financing Cash Flow
13,100
7,860
2,330
140
6,854
Net Change in Cash
6,822
21
78
4,545
753
Free Cash Flow
6,827
8,355
2,428
4,750
11,965
Other Sources
2
-
-
-
-
Exchange Rate Effect
16
9
19
11
192

About CKD Bio

View Profile
Address
Chongkundang Building
Seoul SL 03742
Korea, Republic Of
Employees -
Website http://www.ckdbio.com
Updated 07/08/2019
CKD Bio Corp. engages in the manufacture and sale of raw material medicine. Its products include potassium clavulanate, demeclocycline, rifampicin, and acarbose. The company was founded on November 12, 2001 and is headquartered in Seoul, South Korea.